37 results about "Glutarimide" patented technology

The invention discloses heat-resistant polymethyl methacrylate, a preparation method thereof and an optical film. The heat-resistant polymethyl methacrylate comprises a methyl methacrylate repetitive unit, a glutarimide repetitive unit and an N-methyl methacrylamide repetitive unit, and the sum of the number of the glutarimide constitutional unit and the number of the N-methyl methacrylamide constitutional unit is 1-20 mol% of the total number of the constitutional units. The glutarimide structural unit can be obtained by further cyclization reaction of an N-methyl methacrylamide structural unit, and the cyclization rate can be increased to 80-90% by adding a cyclization accelerator such as triethylamine, so that the thermal stability of the resin is improved, and the water absorption rate is reduced. The material can be used for preparing an optical film, has excellent heat resistance and moisture resistance, and is suitable for the field of optical display.

This invention provides Degron compounds which bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail. Alternatively, the Degron can be linked to a Targeting Ligand which binds to a Target Protein for protein degradation.

The application discloses a bacteriostatic and deodorizing zeolite cat litter and a preparation method thereof, and belongs to the technical field of zeolite cat litter preparation. The bacteriostatic and deodorizing zeolite cat litter is composed of the following components in parts by weight: 55-75 parts of modified zeolite, 3-6 parts of bacteriostatic gel, 2-5 parts of adhesive, and 1-3 parts of filler. The modified zeolite is prepared from sulfamic acid, N,N-dimethylformamide, lignocellulose and zeolite, and the bacteriostatic agent is prepared from four-arm polyethylene glycol, succinic anhydride, triethylamine, N-hydroxyl glutarimide, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride and polylysine. The zeolite cat litter prepared by the method has excellent water absorption, antibacterial property and deodorizing property.

This invention belongs to the field of pharmaceutical chemistry technology, and discloses a compound and its uses. Specifically, it relates to a CRBN small molecule ligand compound based on a pyridazine-glutarimide core skeleton (PDG), its composition, and its application. It also relates to a protein degrading agent based on a CRBN small molecule ligand compound based on a pyridazine-glutarimide core skeleton (PDG) and its application. Specifically, the CRBN small molecule ligand compound is shown in (Ⅰ): wherein R... 1 and R 2 Selected from one or more of the following: fused rings attached to a pyridazine core, H, alkyl, OR, F, CN, CF3, NR2, Ph, 4-Py; Y selected from one or more of CH, CD, CF, and N; R 3 Selected from one or more of OR, NR2, CHR2, and C≡CR; R 4 Selected from H or alkyl.

The present disclosure relates to a compound of Formula (I) or a salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor. The present disclosure also relates to a compound of Formula (I′) or a pharmaceutically acceptable salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor.

The present invention provides degron bodies with carbon-linked E3 ubiquitin ligase targeting moieties (degrons) that can be linked to targeting ligands for proteins selected for degradation in vivo, methods and compositions for their use, and methods for their preparation.

The present invention provides a method for manufacturing acrylic resins, acrylic resin films, and acrylic resin molded articles that exhibit excellent resistance to roll contamination and heat resistance during film formation. [Solution] The method for producing an acrylic resin molded article includes a step of melt-molding an acrylic resin using an extruder, the resin containing methyl methacrylate units and having one or more ring structures selected from the group consisting of glutarimide rings, lactone rings, maleic anhydride rings, glutaric acid anhydride rings, and maleimide rings in its main chain. If the content of methyl methacrylate dimers in the acrylic resin and the content of methyl methacrylate dimers in the acrylic resin molded article are A [ppm by weight] and B [ppm by weight], respectively, then the formula [(AB) / A] × 100 The reduction rate of methyl methacrylate dimers calculated by this method is 50% or more.

The present disclosure provides a compound of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof and uses thereof. The present disclosure also provides pharmaceutical compositions comprising, as an active ingredient, the compound of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof and uses thereof. The series of compounds designed and synthesized in the present disclosure can effectively prevent and / or treat diseases or disorders associated with the cereblon protein.

This invention provides Degron compounds which bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail. Alternatively, the Degron can be linked to a Targeting Ligand which binds to a Target Protein for protein degradation.

The present disclosure relates to the technical field of molecular glue decomposers, and in particular to a compound of formula I based on a sulfur / oxygen substituted glutarimidylimide isoindolinone skeleton and its applications. The present disclosure further relates to a compound of formula A and its applications. JPEG2026502207000117.jpg44146

The present disclosure relates to the technical field of molecular glue degraders, and particularly to a sulfur / oxygen substituted glutarimide-isoindolinone skeleton-based compound of Formula I, and uses thereof. The present disclosure further pertains to a compound of Formula A and its uses.

A resin composition containing 30 to 85 parts by mass of an acrylic resin (A) and 15 to 70 parts by mass of an aromatic vinyl resin (B), wherein the acrylic resin A contains 60 to 95% by mass of (meth)acrylic monomer units and 5 to 40% by mass in total of at least one selected from the group consisting of glutaric anhydride units, glutarimide units, N-substituted maleimide units, and lactone ring units, and the aromatic vinyl resin (B) contains 55 to 93% by mass of aromatic vinyl monomer units and 7 to 45% by mass of N-substituted maleimide units. A plate-shaped molded article and a multilayered article are provided.

The present disclosure relates to a compound of Formula (I) or a salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor. The present disclosure also relates to a compound of Formula (I′) or a pharmaceutically acceptable salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor.

The application relates to the field of organic synthesis, in particular to a preparation method and application of a glutarimide compound, which comprises the following steps: reacting a compound II and a formamide in the presence of formic acid to prepare a compound I. The preparation method adopts glutaric acid compounds and formamide as starting materials, only needs to add a catalytic amount of formic acid in a reaction system, and can obtain a yield of more than 80% without using any additional reaction solvent.

The present invention relates to an isoindolinone derivative compound having a glutarimide mother nucleus, and the application thereof and, more specifically, to an isoindolinone derivative compound having a glutarimide mother nucleus having a thalidomide analog. The compound of chemical formula 1 according to the present invention specifically binds to the CRBN protein and is involved in functions thereof. Thus, the compound of the present invention may be beneficially used in the prevention or treatment of leprosy, chronic graft versus host disease, inflammatory diseases, or cancer that are caused by actions of the CRBN protein.

The present disclosure provides compounds of formula (I): which induce proteolysis of the proto-oncogene tyrosine protein kinase receptor (RET), which may be either wild-type or mutant RET (useful in the treatment of diseases and disorders mediated by said protein): This relates to the compound represented by TIFF2026506696000135.tif42150.

The present invention provides amine-linked C3-glutarimide degradation determinants and degradation determinants for therapeutic applications as further described herein, methods of use and compositions thereof, and methods of their preparation.

In one aspect, the disclosure relates to compounds of Formula (I) comprising a cereblon degrader precursor comprising an acyclic glutarimide moiety. In certain embodiments, the acyclic glutarimide moiety7 converts to a glutarimide moiety7 upon exposure to a stimulus. In certain embodiments, the compound of Formula (I) comprises at least one selected from the group consisting of a Proteolysis Targeting Chimera (PROTAC). degrader antibody conjugate (DAC), and / or Immunomodulatory Imide Drug (IMiD). In another aspect, the disclosure relates to methods of use of the compounds described herein for the treatment of a disease or disorder, including but not limited to cancer.

The application belongs to the technical field of medicine synthesis process, and particularly relates to a preparation method of high-yield and high-purity buspirone hydrochloride. The application takes 8-(2-pyrimidyl)-8-azido-5-5-azospiro[4.5]decane hydrobromide (referred to as pyrimidine piperazine quaternary ammonium salt) and 3,3-tetramethylene glutarimide as raw materials, takes a mixed solvent of toluene, normal pentanol and / or normal hexanol as a solvent, does not need to add a phase transfer catalyst, and can generate buspirone in the presence of sodium carbonate. After acid adjustment and extraction, toluene is removed in the reverse phase, the water phase is adjusted to be alkaline, toluene is extracted, hydrogen chloride ethanol solution is added, and buspirone hydrochloride solid is directly precipitated. The preparation process has a good removal effect on impurities, the obtained buspirone hydrochloride has high purity, high process yield, good atomic economy and small three-waste output.

The present invention relates to: an isoindolinone derivative compound having a glutarimide mother nucleus in which quinoline is substituted; and application thereof, and, more specifically, to an isoindolinone derivative compound having a glutarimide mother nucleus, in which quinoline is substituted, with a thalidomide analog structure. A compound of chemical formula 1, according to the present invention, specifically binds to a CRBN protein and is involved in functions thereof. Therefore, the compound of the present invention can be effectively used in the prevention or treatment of leprosy, chronic graft versus host disease, inflammatory diseases or cancer, which are caused by activity of the CRBN protein.

Provided are a compound of formula (I) or a salt, an enantiomer, a stereoisomer, a solvate, an isotope-enriched analogue, a prodrug or a polymorph thereof, and uses thereof. A pharmaceutical composition comprising a compound of formula (I) as an active ingredient or a salt, enantiomer, stereoisomer, solvate, isotope-enriched analogue, prodrug or polymorph thereof, and uses thereof are provided. The invention further provides application of the compound shown in the formula (II) or salt, enantiomer, stereoisomer, solvate, isotope-enriched analogue, prodrug or polymorphic substance thereof.

Relates to a compound as shown in formula (I), a compound as shown in formula (I ') or salt, enantiomer, stereoisomer, solvate, polymorphic substance and application thereof. The invention also relates to a pharmaceutical composition containing the compound of the formula (I), the compound of the formula (I ') or salts, enantiomers, stereoisomers, solvates and polymorphs thereof as active ingredients and application of the pharmaceutical composition. A series of designed and synthesized compounds can be used for effectively preventing or treating diseases or symptoms related to the cerebron protein.

This invention provides Degron compounds which bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail. Alternatively, the Degron can be linked to a Targeting Ligand which binds to a Target Protein for protein degradation.

The invention discloses a series of glutarimide derivatives and application thereof, and particularly discloses a compound shown as a formula (VI-1), and a stereoisomer or pharmaceutically acceptable salt thereof.

The present application relates to the technical field of biology, in particular to a method for synthesizing a pregabalin intermediate by using immobilized hydantoinase. The pregabalin intermediate with an optical purity of more than 99.9% is obtained by catalyzing the reaction of a substrate 3-isobutyl succinimide under the action of immobilized enzyme; wherein the amino acid sequence of the immobilized enzyme is shown in SEQ ID No. 1. The present application is immobilized by using specific enzyme under specific conditions, and the stability and purity of the enzyme are improved after the treatment, the optical purity of the product is more than 99.9%, and 50 batches of stable application are realized.

The invention discloses a compound which is based on a glutarimido isoindolinone skeleton and is shown in a formula (I) or a salt, an enantiomer, a stereoisomer, a solvate, an isotope-enriched analogue, a prodrug or a polymorphic substance of the compound and application of the compound to treatment and prevention of cerebron protein related diseases or symptoms including tumors or cancers.

The application relates to a preparation method of buspirone hydrochloride: (1) 1-(2-pyrimidyl)-piperazine is reacted with hydrogen chloride ethanol solution to prepare 1-(2-pyrimidyl)-piperazine dihydrochloride; (2) 1-(2-pyrimidyl)-piperazine dihydrochloride is reacted with alkali and 1,4-dibromobutane to prepare 1-(4-bromobutyl)-4-(2-pyrimidyl)-piperazine; (3) 1-(4-bromobutyl)-4-(2-pyrimidyl)-piperazine is reacted with alkali and 3,3-tetramethylene glutarimide to prepare 8-[4-[4-(2-pyrimidyl)-1-piperazine]butyl-8-azaspiro[4,5]decane-7,9-diketone; (4) 8-[4-[4-(2-pyrimidyl)-1-piperazine]butyl-8-azaspiro[4,5]decane-7,9-diketone is added into isopropyl alcohol to react to obtain the product. The application improves product purity and reaction yield, does not use a catalyst, reduces cost, and shortens a production cycle.

The invention discloses an amide hydrolase mutant, a biological material, a screening method, a catalyst and application, and compared with wild type amide hydrolase, the amide hydrolase mutant has amino acid residue mutation at the 317th site, or amino acid residue mutation at the 317th site and amino acid residue mutation at the 63rd site, or amino acid residue mutation at the 317th site, amino acid residue mutation at the 63rd site and amino acid residue mutation at the 65th site. The catalytic efficiency of the mutant can reach 16 times as high as that of wild type amide hydrolase, the yield of R-isobutylglutaric acid monoamide generated by catalyzing isobutylglutaric imide reaches 99%, the stereoselectivity ee value is greater than 99%, the reaction condition is mild, the reaction can be carried out only at 20-45 DEG C, and the mutant has high industrial application value.

This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

The present invention provides amine-linked C3-glutarimide degradation determinants and degradation determinants for therapeutic applications as further described herein, methods of use and compositions thereof, and methods of their preparation.